<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03997929</url>
  </required_header>
  <id_info>
    <org_study_id>2019PI074</org_study_id>
    <nct_id>NCT03997929</nct_id>
  </id_info>
  <brief_title>Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2)</brief_title>
  <acronym>pBDG2</acronym>
  <official_title>Prospective Evaluation of 1.3-ß-D-glucan in the Peritoneal Fluid for the Diagnosis of Fungal Peritonitis in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      New rapid diagnostic strategies are warranted in intra-abdominal candidiasis (IAC). A
      previous retrospective study showed that one measure, the day of the surgery, of peritoneal
      1.3-Beta-D-Glucan ≤ 310pg/ml could rule out an IAC. This strategy was independent of the
      patient underlying conditions and Candida risk factors. This study aimed to confirm these
      results with a multicenter prospective study
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Days</target_duration>
  <primary_outcome>
    <measure>Measure of 1.3 BDG in the peritoneal exudate of patient with intra-abdominal candidiasis</measure>
    <time_frame>1 DAY</time_frame>
    <description>Value of 1.3 BDG in the peritoneal exudate in patient with intra-abdominal candidiasis in comparison with non intra-abdominal candidiasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of 1.3 BDG in the serum of patient with intra-abdominal candidiasis</measure>
    <time_frame>DAY 1 and DAY 3</time_frame>
    <description>Coefficient of correlation between peritoneal and serum 1.3 BDG in patient with and without intra-abdominal candidiasis</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Intra Abdominal Infections</condition>
  <condition>Candidiasis, Invasive</condition>
  <condition>Peritoneal Candidiasis</condition>
  <condition>Critically Ill</condition>
  <arm_group>
    <arm_group_label>CASE (intra abdominal candidiasis)</arm_group_label>
    <description>Critically ill patients with a confirmed diagnosis of intra abdominal candidiasis (IAC) Definition of IAC : sterilely collected peritoneal fluid cultures that are positive for Candida spp. as determined by the signs and symptoms consistent with an active infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL (bacterial intra abdominal infection)</arm_group_label>
    <description>Critically ill patients with a non candida intra abdominal infection (bacterial peritonitis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>1.3 BETA D GLUCAN</intervention_name>
    <description>dosage of 1.3 BETA D GLUCAN in the peritoneal fluid obtained during surgery with the FUNGITELL test (Associate of CAPE COD)</description>
    <arm_group_label>CASE (intra abdominal candidiasis)</arm_group_label>
    <arm_group_label>CONTROL (bacterial intra abdominal infection)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Inclusion of 200 patients. Among them, identification of : 50 Cases (confirmed intra
        abdominal candidiasis) and 50 controls (intra abdominal infection without candida).

        If more than 50 cases, random selection. Identification of control by matching (with
        confounding factors of the 1.3 BDG test). If more than 50 controls after matching, random
        selection.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  critically ill adult (&gt; 18 yrs old) admitted to ICU for intra-abdominal infection
             requiring surgery and possible intra abdominal candidiasis

        Exclusion Criteria:

          -  declinate to participate,

          -  expected death within the first 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel NOVY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Hospital, Nancy, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuel NOVY, MD</last_name>
    <phone>+33383157437</phone>
    <email>e.novy@chru-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>El Mehdi SIAGHY</last_name>
    <phone>+3383155276</phone>
    <email>m.siaghy@chru-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHR Mercy</name>
      <address>
        <city>Metz</city>
        <state>Lorraine</state>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume LOUIS, MD</last_name>
      <phone>00 33 387186214</phone>
      <email>g.louis@chr-metz-thionville.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PILI-FLOURY Sebastien</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BOUHEMAD Belaid</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>POTTECHER Julien</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Novy E, Laithier FX, Machouart MC, Albuisson E, Guerci P, Losser MR. Determination of 1,3-β-D-glucan in the peritoneal fluid for the diagnosis of intra-abdominal candidiasis in critically ill patients: a pilot study. Minerva Anestesiol. 2018 Dec;84(12):1369-1376. doi: 10.23736/S0375-9393.18.12619-8. Epub 2018 Jul 9.</citation>
    <PMID>29991219</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Available from inclusion to end of participation of the included patient</ipd_time_frame>
    <ipd_access_criteria>Only access to IPD of patient of the own participating ICU Access by code</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

